OCTAVE und OPERA: Missklaenge der Hypertonietherapie? [OCTAVE and OPERA: discordance in hypertension therapy?]
Autor/innen
- S. Philipp
- R. Dietz
- R. Willenbrock
Journal
- Herz
Quellenangabe
- Herz 29 (3): 266-270
Zusammenfassung
While ACE-inhibitors have proven their prognostic benefit in many hypertension studies, a new approach has been proposed by inhibiting neutral endopeptidase, which degrades natriuretic peptides. The combined inhibition of ACE and endopeptidase was named “vasopeptidase-inhibition” and tested in several trial. Though effective in lowering blood pressure, a superiority to ACE-inhibitors alone could not be shown. A potentially serious side effect was the increased incidence of angioneurotic edema, which led to a complete stop in the development of this pharmaceutical strategy.